For example, the Akt inhibitor ipatasertib re-sensitized androgen-independent cells to antiandrogens, and, when combined with the androgen receptor antagonist enzalutamide, led to remarkable tumor cell growth inhibition, both in vitro and in vivo [94]. The gene discussed is AKT1; the disease is neoplasm.